Strong Analyst Confidence in C4 Therapeutics (CCCC)’s Cemsidomide Drives 270% Upside Potential

C4 Therapeutics, Inc. (NASDAQ:CCCC) is included successful our database of the 7 astir volatile stocks nether $5 for time trading.

As of February 16, 2026, each of the analysts who screen C4 Therapeutics, Inc. (NASDAQ:CCCC) stay bullish connected the stock. Their statement terms people of $7.00 indicates a 270.37% upside, which reflects their content successful Cemsidomide, the company’s superior degrader.

On January 14, 2026, C4 Therapeutics, Inc. (NASDAQ:CCCC) laid retired cardinal objective and regulatory milestones done 2028, including plans to execute accelerated support for Cemsidomide successful relapsed/refractory aggregate myeloma.

With an NDA submission targeted by year-end 2028 and archetypal ORR information anticipated successful 2H 2027, C4 Therapeutics, Inc. (NASDAQ:CCCC) intends to motorboat the Phase 2 MOMENTUM proceedings successful Q1 2026 for patients who are fourth-line oregon later. In patients with second-line oregon aboriginal disease, a Phase 1b operation survey involving elranatamab is scheduled to commencement successful Q2 2026, portion a Phase 3 proceedings is anticipated by aboriginal 2028.

Based connected 2025 Phase 1 data, Cemsidomide showed ORRs of 40% and 53% astatine 75 µg and 100 µg, respectively. With partnerships with Merck KGaA, Roche, and Biogen, C4T hopes to record up to 3 INDs by 2028 from its neuro- and inflammation programs, successful summation to its oncology programs.

C4 Therapeutics, Inc. (NASDAQ:CCCC), a clinical-stage biopharmaceutical company, uses its Degronimid level to make small-molecule degraders that selectively destruct disease-driving proteins successful neurodegenerative, inflammatory, and cancerous diseases.

While we admit the imaginable of CCCC arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.

Disclosure: None.